Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its investigational SHR-4849 injection. The therapy is intended for the treatment of advanced malignant solid tumors.
The biologic preparation, developed in-house, is designed to specifically target and bind to antigens present on the surface of tumor cells, thereby effectively killing the cancer cells. Hengrui has invested a significant amount of RMB 26.32 million in the development of this molecule to date. The company also notes that there are currently no similar products that have been approved for use in China or anywhere else in the world.- Flcube.com
